Organization · Venture Capital
SCI Ventures
SCI Ventures is a venture-philanthropy fund focused on investing in early-stage companies developing therapies for spinal cord injuries and related conditions. It operates globally, emphasizing scientific rigor and clinical impact.
Overview
What SCI Ventures does
What SCI Ventures is
SCI Ventures is a venture-philanthropy fund focused on investing in early-stage companies developing therapies for spinal cord injuries and related conditions. It operates globally, emphasizing scientific rigor and clinical impact.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2024
- Approximate age
- About 2 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find SCI Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
SCI Ventures as a funder
Investment thesis
SCI Ventures follows a venture-philanthropy model, deploying capital to seek financial returns while focusing on innovative cures for paralysis and related neurological conditions. The fund prioritizes clinical impact and scientific maturity in its investment strategy.
Focus narrative
SCI Ventures invests in companies advancing cures for paralysis-related challenges, emphasizing long-term neural pathway restoration and immediate clinical impact. The fund typically targets Seed and Series A stages, focusing on technologies that address spinal cord injury and adjacent neurological conditions, guided by community priorities and scientific rigor.
Value beyond capital
SCI Ventures adds value to its portfolio companies by bridging the gap between promising lab science and clinical application through financial and operational support. The fund emphasizes de-risking assets and enhancing the potential for clinical impact and commercial success in the field of spinal cord injury and related therapies.
Focus and fit
- Stages
- Seed · Series A
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Notable portfolio companies include: NervGen Pharma: Developing drug treatments for central nervous system regeneration, showing promise in motor recovery for chronic paralysis. Axonis Therapeutics: Focused on small molecule drugs for neuron restoration, with a clinical trial planned for 2024/25. EG 427: A gene therapy platform targeting specific neuronal populations, applicable in neurogenic detrusor overactivity. Healx: An AI-based drug discovery company collaborating with SCI Ventures on a neuro-regeneration program for chronic SCI. Precision Neuroscience: Developing brain-computer interfaces to restore environmental interaction. Sania Therapeutics: A gene therapy platform targeting dysfunctional neural circuits, preparing for IND-enabling studies. Onward Medical: Specializing in spinal cord stimulation to restore movement, with FDA approval expected in 2024. Augmental: Creator of the MouthPad, an in-mouth interface for hands-free human-computer interaction.
Common questions
What to know about SCI Ventures
Upseed classifies SCI Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.